Properties
What is it?
Composition: 1ml of the preparation contains: Active substance: Ketorolac tromethamine - 30.0mg. Excipients: Ethanol 96% - 100.0mg, Sodium chloride - 4.35mg, Disodium edetate dihydrate - 0.50mg, 1 M Sodium hydroxide solution or Hydrochloric acid solution - to pH 7.4-7.5, Water for injections - up to 1ml. Indications: Severe and moderate pain syndrome: trauma, toothache, postoperative pain, oncological diseases, myalgia, arthralgia, neuralgia, radiculitis, sprains, strains, fractures, rheumatological diseases. It is prescribed for symptomatic treatment, however, the reduction of pain and inflammation as a result of taking the preparation does not affect the progression of the disease. Contraindications: Hypersensitivity, bronchial asthma completely or partially associated with ketorolac, recurrent nasal and paranasal polyposis and intolerance to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (including history), urticaria, rhinitis caused by taking non-steroidal anti-inflammatory drugs (in history), intolerance to pyrazolone derivatives, hypovolemia (regardless of its cause), erosive-ulcerative lesions of the gastrointestinal tract in the exacerbation stage, hypocoagulation (including hemophilia), bleeding or high risk of its development, acute renal failure (creatinine clearance <30ml/min), acute liver failure or active liver disease, post-aortocoronary bypass period, confirmed hyperkalemia, inflammatory bowel diseases, childbirth, lactation, children under 16 years of age (efficacy and safety of the preparation have not been established). Pregnancy and lactation: Contraindicated during pregnancy. Lactation should be discontinued during treatment. Administration and dosage: Intramuscular, intravenous. Intravenous administration should be carried out over at least 15 seconds (for dosage forms containing ethanol). In patients aged 16-64 years with a body weight exceeding 50kg, no more than 60mg is administered intramuscularly at a time (considering oral intake); usually 30mg every 6 hours; intravenously - 30mg (no more than 15 doses in 5 days). In adult patients with a body weight less than 50kg or with chronic renal failure, no more than 30mg is administered intramuscularly at a time (including oral dose); usually 15mg is prescribed (no more than 20 doses in 15 days); intravenously - no more than 15mg every 6 hours (no more than 20 doses in 5 days). The maximum daily dose for intramuscular and intravenous injections in patients aged 16-64 years with a body weight exceeding 50kg is 90mg/day; in adult patients with a body weight <50kg or with chronic renal failure, as well as in the elderly (>65 years) - 60mg/day intramuscularly and intravenously. The duration of treatment should not exceed 5 days
